Dr. Parsons has over 25 years of experience in global pharmaceutical development of drugs and biologics. Prior to joining Longboard, Dr. Parsons was Senior Director of Regulatory Affairs at Xencor where she provided regulatory tactical and strategic oversight of the company’s dual checkpoint inhibitor immuno-oncology program targeting solid tumors. At Dart NeuroScience, Dr. Parsons built and led the Regulatory Affairs and Document Management teams responsible for lifecycle management and regulatory strategy of CNS therapeutics. Prior to this, Dr. Parsons managed the lifecycle of Somaxon Pharmaceuticals’ early stage 505(b)(2) products directed toward the treatment of impulse and movement disorders and addiction, and implemented the registration strategy for Silenor® for the treatment of insomnia. At Elan Pharmaceuticals, Dr. Parsons served as Regulatory Project Lead supporting global registration of Tysabri® for treatment of multiple sclerosis and Crohn’s disease, and development of natalizumab for treatment of rheumatoid arthritis and ulcerative colitis. Prior to this, Dr. Parsons assumed various roles of increasing responsibility within Development Chemistry and later Regulatory Affairs at Ionis Pharmaceuticals, where she contributed to the development of antisense oligonucleotide therapeutics targeting cytomegalovirus (CMV) retinitis (Vitravene®) and various autoimmune diseases. Dr. Parsons holds a B.S. in Chemistry from the University of Miami, and a Ph.D. in Chemistry from Emory University.